ArticleScientific reports2025
Bioinformatics approach for discovery of potential lead compound of NSP6 of SARS-CoV-2 using structure based virtual screening and molecular dynamics simulations.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Polyphenol-RichNutrients · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-Structural Protein 6 (NSP6) is a crucial protein for SARS-CoV-2 as it performs a vital role in the replication and transcription of the virus. NSP6 plays a role in the stress response of the endoplasmic reticulum through binding to the sigma receptor 1 (SR1). Therefore, NSP6 is an interesting target for fighting SARS-CoV-2. The best model of the tertiary structure of NSP6 was predicted using the AlphaFold server, then this model was refined using the DeepRefiner server to construct a good-quality model. The current study utilized the virtual screening of the ZINC20 database for the identification of possible inhibitors using the computational docking Autodock Vina program and the post-docking analysis of energy calculations and interactions followed by ADMET studies which were widely used in potential hit identification and lead optimization. From the final hits, our study revealed the best eight compounds that have more potential to be considered as lead compounds for inhibition of a vital role of NSP6 in the replication and transcription of the virus with docking score and binding energy (E_score) with values ranging from - 49.64 to - 43.13 and all these compounds displayed no cellular cytotoxicity. These complexes in addition to the apoprotein were validated and analyzed using molecular dynamic simulations (MDS) for 100 ns. The NSP6-ZINC-141,457,420, NSP6-ZINC-075486396 complexes, revealed the highest complexes in H-bonds formation, NSP6-ZINC-018529632 complex was found to have the lowest binding energy score and NSP6-ZINC-089639800, NSP6-ZINC-157,610,683, NSP6-ZINC-075484852, NSP6-ZINC-016611776, and NSP6-ZINC-141,457,420 complexes presented no a significant deviation from the NSP6-apo protein in the Rg and SASA analysis and revealed promising performance in the RMSD and RMSF. This study exhibited that ZINC-141,457,420, ZINC-075486396, and ZINC-018529632 ligands have a promising potential for development as potential vaccines inhibiting SARS-CoV-2 NSP6 protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.